Ascletis Pharma Inc. (HKG: 1672) announced positive results from a randomized, double‑blind, placebo‑controlled 28‑day proof‑of‑concept clinical trial of ASC50 in U.S. patients with mild‑to‑moderate plaque psoriasis. ASC50 is an in‑house discovered, orally administered small‑molecule IL‑17A inhibitor — a New Chemical Entity (NCE) with a novel scaffold — that achieved a placebo‑adjusted PASI score reduction of 48.9% after 28 days of once‑daily dosing, with sustained effects and a 6.5‑day half‑life supporting potential once‑weekly oral administration.
Regulatory Milestone
| Item | Detail |
|---|---|
| Company | Ascletis Pharma Inc. (HKG: 1672) |
| Asset | ASC50 — oral small‑molecule IL‑17A inhibitor (NCE, novel scaffold) |
| Trial Type | Randomized, double‑blind, placebo‑controlled 28‑day proof‑of‑concept (PoC) trial |
| Population | U.S. patients with mild‑to‑moderate plaque psoriasis |
| Regimen Tested | 200 mg once daily for 28 days |
| Headline Result | Placebo‑adjusted PASI reduction of 48.9% |
| Announcement Date | 29 Sep 2026 |
| Next Steps | Not disclosed (further development plans and trial design) |
Drug Profile & Mechanism of Action
- Molecule: ASC50 — an in‑house discovered, orally administered small molecule, a New Chemical Entity featuring a novel scaffold.
- Target: IL‑17A — a fully validated biological target with established commercial value across various autoimmune and inflammatory diseases, including psoriasis.
- Mechanism Advantage: As a small molecule, ASC50 aims to deliver the validated IL‑17A blockade currently dominated by injectable biologics in an oral format, potentially improving patient convenience, adherence, and access.
- Pharmacokinetics: Steady‑state elimination half‑life of 6.5 days after 28 days of treatment — supporting a potential once‑weekly oral dosing regimen.
Clinical Evidence – 28‑Day Proof‑of‑Concept Trial
| Endpoint | Result (ASC50 200 mg QD × 28 days) | Comparator | Relative Benefit |
|---|---|---|---|
| PASI Score Reduction (Day 28) | Placebo‑adjusted reduction of 48.9% | Placebo | Clinically meaningful efficacy in mild‑to‑moderate disease |
| Steady‑State Elimination Half‑Life | 6.5 days | – | Supports potential once‑weekly oral dosing |
| Sustained Effect – Day 15 After Last Dose | Placebo‑adjusted PASI reduction of 65.9% | Placebo | Continued improvement off‑drug; supports weekly regimen |
The trial enrolled U.S. patients with mild‑to‑moderate plaque psoriasis and evaluated ASC50 at 200 mg once daily for 28 days. Efficacy deepened after treatment cessation: on Day 15 following the last (28th) dose, the placebo‑adjusted PASI reduction reached 65.9%, demonstrating a sustained and improving clinical effect consistent with the compound’s long half‑life and reinforcing the feasibility of once‑weekly oral administration.
Market Impact & Outlook
- Oral Challenge to Injectables: The IL‑17A class is commercially established but delivered almost exclusively via injection. An oral small molecule with validated‑target efficacy could expand the addressable psoriasis population — particularly patients reluctant to use injectables or with mild‑to‑moderate disease under‑served by current biologics.
- Dosing Differentiation: The 6.5‑day half‑life and sustained post‑treatment PASI improvement position ASC50 for a once‑weekly oral regimen, a convenience profile exceeding daily oral therapies in the class.
- De‑Risked Target, Novel Molecule: Building on IL‑17A — a target with proven commercial value — while contributing a novel‑scaffold NCE discovered in‑house combines biological certainty with intellectual‑property differentiation.
- Development Stage: These Phase II‑caliber PoC results in the U.S. support advancement toward pivotal development; trial size, safety profile details, and subsequent program timelines were not disclosed.
- Broader Franchise Potential: Given IL‑17A’s validated role across multiple autoimmune and inflammatory diseases, ASC50 may hold expansion potential beyond psoriasis; no additional indication plans were disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory milestones, and commercial expectations for ASC50. Actual results may differ materially due to risks including confirmatory trial outcomes, safety findings in larger populations, regulatory approvals, and competitive dynamics in oral immunology therapies.-Fineline Info & Tech
